## Abstract ## Background: This randomized double blind, placebo‐controlled crossover study investigated the antidyskinetic effects of levetiracetam in Parkinson's disease. ## Methods: Sixteen participants with levodopa‐induced dyskinesia were enrolled. Hourly videotaped dyskinesia assessments s
Levetiracetam for levodopa-induced dyskinesia in Parkinson’s disease: a randomized, double-blind, placebo-controlled trial
✍ Scribed by Martin Wolz; Matthias Löhle; Karl Strecker; Uta Schwanebeck; Christine Schneider; Heinz Reichmann; Xina Grählert; Johannes Schwarz; Alexander Storch
- Publisher
- Springer
- Year
- 2010
- Tongue
- English
- Weight
- 255 KB
- Volume
- 117
- Category
- Article
- ISSN
- 1435-1463
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract The objective of this study is to conduct a dose‐finding study of sarizotan in Parkinson's disease (PD) patients with dyskinesia to identify a safe dose and to identify a sensitive dyskinesia rating measure. Sarizotan is a novel compound with full 5‐HT~1A~ agonist properties and additio
## Abstract The objective of this study was to investigate the effectiveness of levetiracetam for the treatment of tics in children with Tourette syndrome (TS). Levetiracetam, an atypical anticonvulsant, has been suggested in open‐label protocols to be an effective tic‐suppressing agent in individu
## Abstract We quantitatively investigated the effect of carbidopa/levodopa (25/100) on physical fatigue during finger tapping and force generation in a double‐blind, placebo‐controlled crossover study. Parkinson's disease (PD) subjects were randomly assigned to carbidopa/levodopa or placebo for Vi
Olsalazine, consisting of two salicylate radicals linked by an azo-bond, is effective in the treatment of active ulcerative colitis. To test its effect in patients with mild to moderate attacks of Crohn's disease, the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) des